F&P Healthcare investor reality check
ANALYSIS: The market got carried away with the health company’s valuation.
NBR senior journalist Fiona Rotherham speaks with Will Mace.
Fiona Rotherham
Tue, 06 Jun 2023
When Shoeshine talks to analysts or others about NZX and ASX-listed Fisher & Paykel Healthcare (FPH) they always emphasise it has been a global high-performing healthcare company for many years, paying investors good dividends. It’s rightly held up as a Kiwi success story.
FPH is a leader in the
Want to read more? It's easy.
Choose your subscription
Already have an account? Login
Smartphone Only Subscription
NZ$29.95 / monthly
Monthly Premium Online Subscription
NZ$49.95 / monthly
Smartphone Only Annual Subscription
NZ$299.00 / yearly
Yearly Premium Online Subscription
NZ$499.00 / yearly
Premium Group Membership 10 Users
NZ$385+GST / monthly
$38.5 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$660+GST / monthly
$33 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1375+GST / monthly
$27.5 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$2100+GST / monthly
$21 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$999.00 / yearly
Individual
Group membership
NBR Marketplace
Fiona Rotherham
Tue, 06 Jun 2023
Contact the Writer: fiona@nbr.co.nz
News tip? Question? Typo? Let us know: editor@nbr.co.nz
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Company profile
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Related News
Free News Alerts
Sign up to get the latest stories and insights delivered to your inbox – free, every day.
Company profile
Related News
F&P Healthcare investor reality check
Shoeshine,
99377